Transfusion‐transmitted babesiosis in the era of regional screening: Where are cases still emerging?
Transfusion · 2026-04 · 66 (4) · 871-875
DOI: 10.1111/trf.70133 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transfusion, online erschienen am 17.02.2026. Verfasst von Rebecca Townsend und 2 weiteren Autor:innen. Beteiligte Einrichtung: American Red Cross Biomedical Services, Medical and Scientific Office, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Babesiosis, Transfusion Reaction, Blood Donors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Background
To reduce the risk of transfusion‐transmitted babesiosis (TTB), the Food and Drug Administration (FDA) released guidance in 2019 requiring Babesia screening of all donations collected in 14 states on the East Coast and Upper Midwest (Connecticut, Delaware, Massachusetts, Maryland, Maine, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Virginia, and Vermont Minnesota and Wisconsin), plus Washington, DC. The American Red Cross (ARC) implemented Babesia blood donation screening in those areas in May 2020. Screening uses a transcription‐mediated amplification (TMA) nucleic acid test (NAT) on pools of 16 whole‐blood samples. NAT‐reactive samples are tested for B. microti antibody by immunofluorescence assay (IFA). Case Reports From October 2021 to December 2025, the ARC has identified positive donors in four TTB cases. In all instances, the implicated donation was a Babesia untested red blood cell (RBC) unit collected in a non‐endemic state where screening is not performed (West Virginia, Oregon, Georgia, and Michigan). All cases were travel‐related: three donors reported travel to endemic states, while the fourth was a resident of an endemic state who donated during a vacation in a non‐endemic state.
Conclusion
The regional approach of Babesia blood testing has dramatically reduced the risk of TTB. However, the cases described in this report highlight the ongoing vulnerability posed by donor travel and underscore the need to continue monitoring the current geographic screening strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- American Red Cross Biomedical Services, Medical and Scientific Office, Washington, District of Columbia, USA.
- American Red Cross Biomedical Services, Donor and Client Support Center, Charlotte, North Carolina, USA.
ORCID-Profile: Laura Tonnetti
Zitieren
APA
Townsend, R., Losco, P., & Tonnetti, L. (2026). Transfusion‐transmitted babesiosis in the era of regional screening: Where are cases still emerging?. Transfusion, 66(4), 871-875. https://doi.org/10.1111/trf.70133
Vancouver
Townsend R, Losco P, Tonnetti L. Transfusion‐transmitted babesiosis in the era of regional screening: Where are cases still emerging?. Transfusion. 2026;66(4):871-875. doi:10.1111/trf.70133
BibTeX
@article{Townsend2026,
author = {Townsend, Rebecca and Losco, Paul and Tonnetti, Laura},
title = {Transfusion‐transmitted babesiosis in the era of regional screening: Where are cases still emerging?},
journal = {Transfusion},
year = {2026},
volume = {66},
number = {4},
pages = {871--875},
doi = {10.1111/trf.70133}
}
EUVIMED